https://cloud.google.com/blog/products/infrastructure-modernization/introducing-blockchain-node-engine
HC Wainwright & Co. Maintains Buy on TCR2 Therapeutics, Lowers Price Target to $13
HC Wainwright & Co. analyst Robert Burns maintains TCR2 Therapeutics (NASDAQ:TCRR) with a Buy and lowers the price target from $14 to $13.